Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jan;41(1):122–128. doi: 10.1128/aac.41.1.122

Evaluation of a brain-targeting zidovudine chemical delivery system in dogs.

M E Brewster 1, W R Anderson 1, A I Webb 1, L M Pablo 1, D Meinsma 1, D Moreno 1, H Derendorf 1, N Bodor 1, E Pop 1
PMCID: PMC163672  PMID: 8980767

Abstract

AIDS encephalopathy is an insidious complication of human immunodeficiency virus infection which is difficult to treat because of the poor uptake of many potentially useful antiretroviral drugs through the blood-brain barrier. A chemical delivery system (CDS) for zidovudine (AZT) based on redox trapping within the brain has been prepared and tested in several animal models to circumvent this limitation. The behavior of the AZT-CDS in the dog was considered. Parenteral administration of AZT resulted in rapid systemic elimination and poor uptake by the central nervous system. Ratios of the area under the concentration-time curve of AZT for cerebrospinal fluid to that for blood were 0.32, and ratios of the area under the concentration-time curve of AZT for brain to that for blood were approximately 0.25. Administration of an aqueous formulation of the AZT-CDS resulted in rapid tissue uptake and conversion of the CDS to the corresponding quaternary salt with the subsequent production of AZT. Delivered in this way, the levels of AZT in brain were 1.75- to 3.3-fold higher than those associated with conventional AZT administration. In addition, the levels of AZT in blood were 46% lower than those associated with AZT administration. The higher concentrations in brain and lower concentration in blood combined to significantly increase the ratio of the concentration of AZT in the brain to that in blood after AZT-CDS administration compared to that after AZT dosing.

Full Text

The Full Text of this article is available as a PDF (199.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggarwal S. K., Gogu S. R., Rangan S. R., Agrawal K. C. Synthesis and biological evaluation of prodrugs of zidovudine. J Med Chem. 1990 May;33(5):1505–1510. doi: 10.1021/jm00167a034. [DOI] [PubMed] [Google Scholar]
  2. Bodor N., Brewster M. E. Problems of delivery of drugs to the brain. Pharmacol Ther. 1982;19(3):337–386. doi: 10.1016/0163-7258(82)90073-0. [DOI] [PubMed] [Google Scholar]
  3. Bodor N., Farag H. H., Brewster M. E., 3rd Site-specific, sustained release of drugs to the brain. Science. 1981 Dec 18;214(4527):1370–1372. doi: 10.1126/science.7313698. [DOI] [PubMed] [Google Scholar]
  4. Brew B. J., Rosenblum M., Price R. W. AIDS dementia complex and primary HIV brain infection. J Neuroimmunol. 1988 Dec;20(2-3):133–140. doi: 10.1016/0165-5728(88)90144-0. [DOI] [PubMed] [Google Scholar]
  5. Brewster M. E., Anderson W. R., Helton D. O., Bodor N., Pop E. Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Pharm Res. 1995 May;12(5):796–798. doi: 10.1023/a:1016240432455. [DOI] [PubMed] [Google Scholar]
  6. Brewster M. E., Anderson W., Bodor N. Brain, blood, and cerebrospinal fluid distribution of a zidovudine chemical delivery system in rabbits. J Pharm Sci. 1991 Sep;80(9):843–846. doi: 10.1002/jps.2600800908. [DOI] [PubMed] [Google Scholar]
  7. Brewster M. E., Bodor N. Redox approaches to drug delivery to the central nervous system. NIDA Res Monogr. 1992;120:169–201. [PubMed] [Google Scholar]
  8. Brewster M. E., Estes K. S., Loftsson T., Perchalski R., Derendorf H., Mullersman G., Bodor N. Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. J Pharm Sci. 1988 Nov;77(11):981–985. doi: 10.1002/jps.2600771118. [DOI] [PubMed] [Google Scholar]
  9. Brewster M. E., Pop E., Braunstein A. J., Pop A. C., Druzgala P., Dinculescu A., Anderson W., Elkoussi A., Bodor N. The effect of dihydronicotinate N-substitution on the brain-targeting efficacy of a zidovudine chemical delivery system. Pharm Res. 1993 Sep;10(9):1356–1362. doi: 10.1023/a:1018986217181. [DOI] [PubMed] [Google Scholar]
  10. Brewster M. E., Raghavan K., Pop E., Bodor N. Enhanced delivery of ganciclovir to the brain through the use of redox targeting. Antimicrob Agents Chemother. 1994 Apr;38(4):817–823. doi: 10.1128/aac.38.4.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bridge T. P., Ingraham L. J. Central nervous system effects of human immunodeficiency virus type 1. Annu Rev Med. 1990;41:159–168. doi: 10.1146/annurev.me.41.020190.001111. [DOI] [PubMed] [Google Scholar]
  12. Brinchmann J. E., Vartdal F., Thorsby E. T lymphocyte subset changes in human immunodeficiency virus infection. J Acquir Immune Defic Syndr. 1989;2(4):398–403. [PubMed] [Google Scholar]
  13. Chu C. K., Bhadti V. S., Doshi K. J., Etse J. T., Gallo J. M., Boudinot F. D., Schinazi R. F. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. J Med Chem. 1990 Aug;33(8):2188–2192. doi: 10.1021/jm00170a023. [DOI] [PubMed] [Google Scholar]
  14. Dykstra K. H., Arya A., Arriola D. M., Bungay P. M., Morrison P. F., Dedrick R. L. Microdialysis study of zidovudine (AZT) transport in rat brain. J Pharmacol Exp Ther. 1993 Dec;267(3):1227–1236. [PubMed] [Google Scholar]
  15. Gallo J. M., Etse J. T., Doshi K. J., Boudinot F. D., Chu C. K. Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice. Pharm Res. 1991 Feb;8(2):247–253. doi: 10.1023/a:1015808624103. [DOI] [PubMed] [Google Scholar]
  16. Gallo J. M., Sanzgiri Y., Howerth E. W., Finco T. S., Wilson J., Johnston J., Tackett R., Budsberg S. C. Zidovudine serum, cerebrospinal fluid, and brain concentrations following chronic administration of a new zidovudine formulation via an implantable pump in dogs [corrected]. J Pharm Sci. 1992 Jan;81(1):11–15. doi: 10.1002/jps.2600810103. [DOI] [PubMed] [Google Scholar]
  17. Glasner P. D., Kaslow R. A. The epidemiology of human immunodeficiency virus infection. J Consult Clin Psychol. 1990 Feb;58(1):13–21. doi: 10.1037/h0092560. [DOI] [PubMed] [Google Scholar]
  18. Gogu S. R., Aggarwal S. K., Rangan S. R., Agrawal K. C. A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochem Biophys Res Commun. 1989 Apr 28;160(2):656–661. doi: 10.1016/0006-291x(89)92483-2. [DOI] [PubMed] [Google Scholar]
  19. Grant I., Heaton R. K. Human immunodeficiency virus-type 1 (HIV-1) and the brain. J Consult Clin Psychol. 1990 Feb;58(1):22–30. doi: 10.1037//0022-006x.58.1.22. [DOI] [PubMed] [Google Scholar]
  20. Hollander H. Neurologic and psychiatric manifestations of HIV disease. J Gen Intern Med. 1991 Jan-Feb;6(1 Suppl):S24–S31. doi: 10.1007/BF02599254. [DOI] [PubMed] [Google Scholar]
  21. Lupia R. H., Ferencz N., Lertora J. J., Aggarwal S. K., George W. J., Agrawal K. C. Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. Antimicrob Agents Chemother. 1993 Apr;37(4):818–824. doi: 10.1128/aac.37.4.818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Masereeuw R., Jaehde U., Langemeijer M. W., de Boer A. G., Breimer D. D. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm Res. 1994 Feb;11(2):324–330. doi: 10.1023/a:1018932213953. [DOI] [PubMed] [Google Scholar]
  23. Mizrachi Y., Rubinstein A., Harish Z., Biegon A., Anderson W. R., Brewster M. E. Improved brain delivery and in vitro activity of zidovudine through the use of a redox chemical delivery system. AIDS. 1995 Feb;9(2):153–158. [PubMed] [Google Scholar]
  24. Pajeau A. K., Román G. C. HIV encephalopathy and dementia. Psychiatr Clin North Am. 1992 Jun;15(2):455–466. [PubMed] [Google Scholar]
  25. Purdy B. D., Plaisance K. I. Infection with the human immunodeficiency virus: epidemiology, pathogenesis, transmission, diagnosis, and manifestations. Am J Hosp Pharm. 1989 Jun;46(6):1185–1209. [PubMed] [Google Scholar]
  26. Reinvang I., Frøland S. S., Skripeland V. Prevalence of neuropsychological deficit in HIV infection. Incipient signs of AIDS dementia complex in patients with AIDS. Acta Neurol Scand. 1991 May;83(5):289–293. doi: 10.1111/j.1600-0404.1991.tb04703.x. [DOI] [PubMed] [Google Scholar]
  27. Sawchuk R. J., Hedaya M. A. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. Pharm Res. 1990 Apr;7(4):332–338. doi: 10.1023/a:1015854902915. [DOI] [PubMed] [Google Scholar]
  28. Terasaki T., Pardridge W. M. Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J Infect Dis. 1988 Sep;158(3):630–632. doi: 10.1093/infdis/158.3.630. [DOI] [PubMed] [Google Scholar]
  29. Tuntland T., Ravasco R. J., al-Habet S., Unadkat J. D. Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. Pharm Res. 1994 Feb;11(2):312–317. doi: 10.1023/a:1018928013044. [DOI] [PubMed] [Google Scholar]
  30. Weber J. The biology and epidemiology of HIV infections. J Antimicrob Chemother. 1989 Jan;23 (Suppl A):1–7. doi: 10.1093/jac/23.suppl_a.1. [DOI] [PubMed] [Google Scholar]
  31. Wong S. L., Hedaya M. A., Sawchuk R. J. Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. Pharm Res. 1992 Feb;9(2):228–235. doi: 10.1023/a:1018993524818. [DOI] [PubMed] [Google Scholar]
  32. Wong S. L., Van Belle K., Sawchuk R. J. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther. 1993 Feb;264(2):899–909. [PubMed] [Google Scholar]
  33. Yarchoan R., Berg G., Brouwers P., Fischl M. A., Spitzer A. R., Wichman A., Grafman J., Thomas R. V., Safai B., Brunetti A. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1987 Jan 17;1(8525):132–135. doi: 10.1016/s0140-6736(87)91968-4. [DOI] [PubMed] [Google Scholar]
  34. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES